Positive new results for Eisai's Lenvima in thyroid cancer

New data show that Japanese pharma major Eisai’s (TYO: 4523) Lenvima (lenvatinib) improves progression-free survival for people with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) regardless of metastatic site, with the exception of the brain.

These lenvatinib Phase III SELECT trial sub-analyses were presented at the 15th International Thyroid Congress (ITC) held in Florida, USA, in an oral session on October 19.

The sub-analysis observed response rates of more than 50% and a progression-free survival benefit among people treated with lenvatinib with common sites of metastasis (bone, liver, lung, lymph node). The study examined 392 patients being treated with lenvatinib versus placebo, and identified metastatic subgroups as an important determinant of progression-free survival for people treated with lenvatinib.